Sandoz Group Ltd (SDZ) AI Stock Analysis

• Market Cap: $26.25B
• Dividend Yield: 1.02%
• Average Volume (3M): 677.45K
• Price to Earnings (P/E): 32.9
• Beta (1Y): 0.75
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CH
• Employees: 22,049
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.47
• Shares Outstanding: 440,000,000
• 10 Day Avg. Volume: 616,025
• 30 Day Avg. Volume: 677,447
• PEG Ratio: 0.00
• Price to Book (P/B): 3.35
• Price to Sales (P/S): 2.71
• P/FCF Ratio: 38.83
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 3.28
• Enterprise Value/Gross Profit: 6.96
• Enterprise Value/Ebitda: 22.49
• 1Y Price Target: $71.19
• Price Target Upside: 19.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 4.03
• Revenue Forecast (FY): $12.07B

• Rating: 66 Neutral
• Price Target: CHF69.00 ▲(15.66% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is led by improving financial performance in 2025 (growth, margins, and stronger operating/free cash flow), tempered by multi-year volatility and rising debt. Technicals are mixed with near-term weakness despite a longer-term uptrend, and valuation looks reasonable on earnings but offers a modest dividend yield.

Positive Factors

Revenue & Profitability Rebound

A clear 2025 recovery (revenue up ~25%, net margin ~8%) signals stronger commercial execution and portfolio momentum. This rebound improves the firm's ability to fund operations and investments, supporting sustainable earnings generation over the next 2–6 months if execution and market access hold.

Consistent Gross Margins

Stable gross margins near the mid‑40s reflect durable manufacturing scale and favorable product economics across generics and biosimilars. Persistent gross profitability provides structural buffer vs. pricing cycles and supports long‑run operating margin resilience.

Improved Cash Generation

Material FCF improvement to ~0.81B and OCF ~1.6B enhances financial flexibility to service debt, invest in capacity or biosimilars commercialization, and return value. Stronger cash conversion increases resilience against cyclical pressure and funds strategic initiatives.

Negative Factors

Earnings and Cash Flow Volatility

Multi‑year swings in net income and FCF reduce forecasting reliability and hinder sustained capital allocation planning. Volatility suggests sensitivity to tender timing, launch competition and working capital cycles, complicating long‑term investment and stakeholder confidence.

Rising Absolute Debt & Data Outlier

Increasing absolute debt raises leverage and interest‑service risk, limiting strategic flexibility. The 2022 balance‑sheet outlier undermines confidence in trend assessment, making it harder to judge sustainable capital structure and credit resilience over the medium term.

Tender/Price Competition Exposure

Heavy reliance on tender and institutional channels exposes margins to competitive price erosion and procurement cycles. Structural commoditization in generics means market share is price‑sensitive, requiring continual scale, cost control and successful biosimilar uptake to preserve long‑term profitability.

Sandoz Group Ltd Business Overview & Revenue Model

Company Description

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

How the Company Makes Money

Sandoz makes money primarily by selling generic medicines and biosimilars to healthcare systems, wholesalers, pharmacies, and hospitals. Its core revenue stream comes from high-volume, price-competitive small-molecule generics, where products are launched after patent expiry of branded drugs and sold through (1) retail channels (via wholesalers and pharmacy supply) and (2) institutional channels such as hospitals and public procurement, where winning tenders and supply contracts can drive large, recurring volumes but often at lower unit prices. A second major revenue stream is biosimilars, which are typically higher-value than traditional generics and generate revenue through commercial agreements and market access with payers and providers; earnings depend on successful regulatory approvals, formulary inclusion, physician adoption, and the ability to offer cost savings versus originator biologics. Across both segments, profitability is influenced by manufacturing scale, cost of goods, product mix (complex generics and injectables can carry different economics than standard oral solids), and the timing/competition intensity of launches in each market. The company also earns revenue from country- and product-specific distribution arrangements and supply relationships, where Sandoz manufactures and sells finished dosage forms (or, where applicable, supplies product to partners) under negotiated commercial terms. Specific named partnerships or the exact breakdown of revenue by stream are null.

Sandoz Group Ltd Financial Statement Overview

Summary

Strong 2025 rebound in revenue growth, profitability, and cash generation, supported by consistently solid gross margins. Offsetting this, earnings and free cash flow have been volatile across recent years, and rising absolute debt plus a 2022 balance-sheet data outlier reduce confidence in trend consistency.

Income Statement

Profitability improved sharply in 2025, with revenue up ~25% and net margin recovering to ~8% after near-breakeven results in 2024. Gross margin has remained consistently strong (~46–48%) across the period, supporting resilient product economics. The key weakness is earnings volatility: net income dropped materially in 2023–2024 before rebounding in 2025, and operating profitability (EBIT margin) has swung meaningfully year to year.

Balance Sheet

Leverage is moderate in the most recent years, with debt running at ~0.6x equity in 2024–2025 and equity building alongside asset growth. Returns on equity rebounded to ~10% in 2025 after being negligible in 2024, consistent with the earnings recovery. Main concerns are rising absolute debt (2023–2025) and a clear data-quality outlier in 2022 (extreme debt-to-equity and return on equity), which reduces confidence in trend consistency.

Cash Flow

Cash generation strengthened meaningfully in 2025: operating cash flow rose to ~1.6B and free cash flow to ~0.81B, a major improvement versus weak/negative free cash flow in 2023 and modest levels in 2024. Free cash flow covered about half of 2025 net income, indicating decent earnings cash conversion, but not best-in-class. The main weakness is variability—free cash flow swung from negative (2023) to modest (2024) to strong (2025), suggesting working-capital and/or investment-cycle sensitivity.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.61B	9.12B	9.98B	8.60B	8.83B
Gross Profit	5.46B	4.31B	4.56B	4.05B	4.20B
EBITDA	1.79B	667.55M	857.00M	1.53B	1.68B
Net Income	957.48M	1.00M	77.00M	784.05M	828.37M
Balance Sheet
Total Assets	22.03B	19.91B	19.43B	100.00K	15.98B
Cash, Cash Equivalents and Short-Term Investments	1.74B	1.19B	933.39M	100.00K	36.45M
Total Debt	5.68B	4.85B	4.55B	309.02M	284.28M
Total Liabilities	12.65B	11.74B	10.78B	22.86K	8.55B
Stockholders Equity	9.38B	8.16B	7.28B	77.14K	7.43B
Cash Flow
Free Cash Flow	810.00M	60.00M	-242.64M	760.23M	855.75M
Operating Cash Flow	1.59B	656.00M	325.31M	1.17B	1.24B
Investing Cash Flow	-980.00M	-740.00M	-551.77M	-410.68M	-631.76M
Financing Cash Flow	-197.00M	242.00M	1.24B	-734.45M	-600.67M

Sandoz Group Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 59.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SDZ, the sentiment is Negative. The current price of 59.66 is below the 20-day moving average (MA) of 64.29, below the 50-day MA of 63.54, and above the 200-day MA of 53.29, indicating a neutral trend. The MACD of -0.98 indicates Positive momentum. The RSI at 36.08 is Neutral, neither overbought nor oversold. The STOCH value of 16.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SDZ.

Sandoz Group Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NOVN	78 Outperform	CHF221.00B	18.30	―	3.18%	7.62%	-18.33%
ROG	75 Outperform	$242.59B	20.28	31.98%	2.94%	4.77%	-11.07%
ALC	72 Outperform	$29.14B	38.35	4.44%	0.44%	0.39%	-12.46%
SDZ	66 Neutral	$26.25B	32.85	2.64%	1.02%	―	―
SFZN	62 Neutral	CHF3.25B	19.36	15.79%	0.51%	0.77%	16.70%
LONN	56 Neutral	CHF31.85B	19.54	―	0.75%	5.93%	29.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sandoz Group Ltd Corporate Events

Sandoz reshapes biosimilar and generics leadership to seize upcoming patent cliff

Sandoz is restructuring to sharpen its focus on biosimilars and generics as it targets a projected “golden decade” of loss-of-exclusivity opportunities worth more than USD 650 billion. The company has created a dedicated global biosimilar development, manufacturing and supply unit, appointing industry veteran Armin Metzger as President of this new division and member of the Executive Committee, while redefining leadership roles in its core generics business.

By consolidating biosimilar activities under a single executive and giving generics its own specialized development and manufacturing heads, Sandoz aims to speed decision-making, deepen vertical integration and tailor strategies to distinct market dynamics in each segment. The move reinforces its positioning as the only pure-play leader across both biosimilars and generics, is intended to strengthen its competitive edge in high-volume generics, and leaves the company’s 2026 financial guidance and medium-term outlook unchanged.

In parallel, Sandoz is streamlining its regional governance by having the German business report into the President Europe, aligning Germany’s representation at the executive committee level with a broader European lens. These organizational changes are designed to unlock biosimilar growth potential, support sustainable expansion, and better capture upcoming market opportunities without altering current financial targets.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF80.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

Sandoz lifts profit, dividend and 2026 outlook on biosimilar-driven growth

Sandoz reported strong full-year 2025 results, with net sales rising 7% in USD to USD 11.1 billion, driven by 15% biosimilar growth and an 8% increase in volumes, while core EBITDA margin expanded 160 basis points to 21.7% and core EPS jumped 34%. The company proposed a higher dividend, guided to mid-to-high single-digit net sales growth and further margin expansion in 2026, supported by a wave of biosimilar and generic launches, strategic acquisitions and licensing deals that deepen its oncology and retinal portfolios, even as pricing pressure in penicillin APIs and tariff-driven trade distortions weigh on its generics business into 2026.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

Sandoz wins EU approval for Ranluspec biosimilar, bolstering ophthalmology push

Sandoz has secured European Commission marketing authorization for Ranluspec, a ranibizumab biosimilar developed with Lupin for treating neovascular age-related macular degeneration and a range of other retinal vascular disorders. Demonstrating equivalent efficacy and comparable safety to Lucentis, the drug targets conditions affecting millions of patients, with launch planned for the second half of 2026.

The approval reinforces Sandoz’s ambitions in ophthalmology and consolidates its broader biosimilars leadership, following the earlier European launch of Afqlir and its strategy to tap a projected USD 320 billion biosimilar market over the coming decade. Under its partnership with Lupin, Sandoz will hold exclusive commercialization rights for Ranluspec in most EU markets, complementing its separate ranibizumab offering in Germany and potentially broadening access to vision-saving therapies for European patients.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

Sandoz Wins Expanded U.S. FDA Label for Enzeevu Retinal Biosimilar

Sandoz has secured U.S. FDA approval to expand the label of its aflibercept biosimilar Enzeevu to cover all major retinal indications, including macular edema following retinal vein occlusion, diabetic retinopathy and diabetic macular edema, in addition to its existing nod for neovascular age-related macular degeneration. With more than 30 million Americans affected by retinal diseases, the broader label and planned U.S. launch in the fourth quarter of 2026 bolster Sandoz’s ophthalmology franchise alongside Cimerli and Afqlir, reinforcing its push to capture a larger share of the fast-growing global biosimilar market and potentially lowering treatment costs for patients and payers.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

Sandoz Wins EU Approval for Ondibta Biosimilar Insulin, Bolstering Diabetes Push

Sandoz has secured European Commission marketing authorization for Ondibta, a biosimilar insulin glargine in a pre-filled pen developed with Gan & Lee Pharmaceuticals, for the treatment of diabetes mellitus in adults, adolescents and children from two years of age, matching the reference product Lantus SoloStar in safety, quality and efficacy. The product, expected to launch by early 2027, is positioned to intensify price competition in Europe’s fast‑growing diabetes market, potentially improving affordability and access for tens of millions of patients as regional diabetes prevalence and related healthcare expenditure continue to climb. The approval strengthens Sandoz’s strategic push into diabetes care, reinforces its long-standing leadership in biosimilars, and supports its broader plan to capture a substantial share of the projected USD 320 billion biosimilar market over the next 10 years through partnership-based commercialization and an expanding pipeline.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF70.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

Sandoz Targets ‘Golden Decade’ as Patent Cliff Opens USD 600 Billion Generics and Biosimilars Opportunity

Sandoz plans to leverage its status as the leading pure‑play biosimilar and generics manufacturer to capture a substantial share of an expected USD 600 billion wave of patent expiries over the next decade. Speaking at the J.P. Morgan Healthcare Conference, CEO Richard Saynor will outline how recent strategic investments in European manufacturing hubs in Slovenia and France, successful biosimilar and generic launches, and a pipeline of more than 400 assets position the company to target roughly two‑thirds of the global generic and about 60% of the biosimilar loss‑of‑exclusivity opportunity, particularly in oral solids, injectables and longer‑term GLP‑1 therapies. Backed by 2024 sales of USD 10 billion and ongoing margin expansion, Sandoz aims to turn this “golden decade” of affordable medicines into accelerated growth and broader patient access, reinforcing its leadership in a market that already accounts for most prescriptions but a minority of total drug spending, and potentially reshaping competitive dynamics and cost pressures across global healthcare systems.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF70.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.